Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.59 |
| ▸ | LTA4H | P09960 | 2/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3664139 | 0.91 | KDM4E (0.65) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL22831355 | 0.89 | KCNH2 (0.53) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL23074666 | 0.85 | MEN1 (0.47) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL12204130 | 0.84 | HRH3 (0.57) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL14923990 | 0.84 | CHRNB2 (0.51) | HRH3KDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL14464042 | 0.84 | ALDH1A1 (0.55) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL10824702 | 0.83 | KMT2A (0.59) | KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL29129692 | 0.83 | HRH3 (0.58) | HRH3LTA4HKEAP1NFE2L2KDM4E | |
| SCHEMBL20322556 | 0.82 | KCNH2 (0.47) | HRH3KEAP1NFE2L2KDM4ESMN1; SMN2 | |
| SCHEMBL16204295 | 0.82 | LTA4H (0.65) | HRH3LTA4HKEAP1NFE2L2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582963-B2 | Separation matrix and method of separation | CYTIVA BIOPROCESS R&D AB (SE) | 2026-03-24 | — | — | US | disclosed |
| US-12343702-B2 | Anionic exchange-hydrophobic mixed mode chromatography resin | BIO-RAD LABORATORIES, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250196100-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESIN | BIO-RAD LABORATORIES, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4142930-B1 | SEPARATION MATRIX AND METHOD OF SEPARATION | PURIDIFY LTD (GB) | 2024-05-08 | — | — | EP | disclosed |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-8084618-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-1458392-B9 | ACRIDONES AS INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2010-07-28 | — | — | EP | disclosed |
| US-7652051-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2008-02-07 | — | — | US | disclosed |
| US-7282498-B2 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282498-B2 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070087346-A1 | Orthogonal gene switches | CILIBERTO GENNARO | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | HRH3 82/4885LTA4H 311/4885KEAP1 336/4885 |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | HRH3 82/4885LTA4H 311/4885KEAP1 336/4885 |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, SMAD3 | HRH3 380/4885LTA4H 761/4885KEAP1 163/4885 |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | HRH3 3296/4885LTA4H 3035/4885KEAP1 2013/4885 |
| US-20250196100-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESIN | SLC7A1, ABCG2, MSR1 | HRH3 6/4885LTA4H 1282/4885KEAP1 3946/4885 |
| US-12582963-B2 | Separation matrix and method of separation | EPCAM, PA2G4, MAG | HRH3 1754/4885LTA4H 2775/4885KEAP1 4329/4885 |
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NPSR1, GABRE, CHRNE | HRH3 235/4885LTA4H 2197/4885KEAP1 4109/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | HRH3 2673/4885LTA4H 3332/4885KEAP1 499/4885 |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | HRH3 489/4885LTA4H 1864/4885KEAP1 2547/4885 |
| US-20070087346-A1 | Orthogonal gene switches | TCF12, JUN, TCF7 | HRH3 4142/4885LTA4H 3485/4885KEAP1 1203/4885 |
| US-12343702-B2 | Anionic exchange-hydrophobic mixed mode chromatography resin | FCGRT, PBRM1, BCR | HRH3 99/4885LTA4H 3846/4885KEAP1 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.